Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer

Table 2

Details for EC subgroups.

Variable	EAC N (%)	nEAC N (%)	ESCC N (%)	nESCC; N (%)
Gender
Male	68 (81.0)	100 (85.5)	21 (65.6)	36 (72.0)
Female	16 (19.0)	17 (14.5)	11 (34.4)	14 (28.0)
UICC stage
0	6 (7.1)	8 (6.8)	2 (6.3)	11 (22.0)
1	51 (60.7)	12 (10.3)	7 (21.9)	5 (10.0)
2	17 (20.2)	35 (29.9)	11 (34.4)	17 (34.0)
3	9 (10.7)	59 (50.4)	12 (37.5)	17 (34.0)
4	1 (1.2)	3 (2.6)	0 (0.0)	0 (0.0)
Adjuvant therapy
Yes	1 (1.2)	24 (20.5)	2 (6.3)	3 (6.0)
No	83 (98.8)	93 (79.5)	30 (93.7)	47 (94.0)
Surgical approach
One-stage	29 (34.5)	20 (17.1)	0 (0.0)	1 (2.0)
Two-stage	55 (65.5)	97 (82.9)	32 (100)	49 (98.0)
CRP > 1
Yes	11 (13.3)	19 (16.7)	7 (21.9)	17 (34.0)
No	72 (86.7)	95 (83.3)	25 (78.1)	33 (66.0)
Alb < 35
Yes	10 (12.0)	14 (12.2)	1 (3.1)	7 (14.0)
No	73 (88.0)	101 (87.8)	31 (96.9)	43 (86.0)
GPS
0	64 (77.1)	86 (75.4)	25 (78.1)	32 (64.0)
1	17 (20.5)	23 (20.2)	6 (18.8)	12 (24.0)
2	2 (2.4)	5 (4.4)	1 (3.1)	6 (12.0)
mGPS
0	72 (86.8)	95 (83.3)	25 (78.1)	33 (66.0)
1	9 (10.8)	14 (12.3)	6 (18.8)	11 (22.0)
2	2 (2.4)	5 (4.4)	1 (3.1)	6 (12.0)
C/A ratio > 0.95
Yes	4 (4.8)	6 (5.3)	1 (3.1)	6 (12.0)
No	79 (95.2)	108 (94.7)	31 (96.9)	44 (88.0)

In four patients, preoperative CRP and/or albumin was not available. EC: esophageal cancer; EAC: esophageal adenocarcinoma; nEAC: neoadjuvant-treated esophageal cancer; ESCC: esophageal squamous cell carcinoma; nESCC: neoadjuvant-treated esophageal squamous cell carcinoma; UICC: Union for International Cancer Control; CRP > 1: preoperative serum C-reactive protein >1 mg/dl; Alb < 35: preoperative serum albumin <35 g/l; GPS: glasgow prognostic score; mGPS: modified Glasgow prognostic score; C/A ratio: ratio from preoperative serum CRP and albumin.